Proposal That Medicare Covers Aduhelm Only for Trials Sparks Outrage

Proposal That Medicare Covers Aduhelm Only for Trials Sparks Outrage

316123

Proposal That Medicare Covers Aduhelm Only for Trials Sparks Outrage

A new proposal in the U.S. that Medicare cover the cost of Aduhelm (aducanumab) only for people enrolled in qualifying clinical trials has been met with outrage from the Alzheimer’s Association and decried by Biogen, which developed the treatment alongside Eisai. Issued by the U.S. Centers for Medicare and Medicaid Services (CMS), the proposed National Coverage Determination would also apply to other monoclonal antibody therapies that work in the same manner as Aduhelm — a…

You must be logged in to read/download the full post.